Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
estimated completion

Description

Summary

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

Official Title

A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients With Hematologic Malignancies

Details

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. The purpose of this 15-year research study is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies as part of a previous Caribou-sponsored study or a Caribou-sponsored special access program.

Keywords

Lymphoma, Non-Hodgkin Relapsed Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma Lymphoma B Cell Lymphoma B-Cell Non-Hodgkin's Lymphoma Hematologic Malignancy Allogeneic CAR-T CB-010 Neoplasms Lymphoma, B-Cell Hematologic Neoplasms Allogeneic CAR-T therapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Written informed consent obtained prior to study-specific activities/enrollment
  • Received an allogeneic CAR-T therapy and completed or discontinued from a Caribou-sponsored study evaluating an allogeneic CAR-T therapy or was administered an allogeneic CAR-T therapy under a special access mechanism

You CAN'T join if...

  • None

Locations

  • University of California Irvine
    Irvine California 92868 United States
  • Baylor Research Institute
    Dallas Texas 75246 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Caribou Biosciences, Inc.
ID
NCT05332054
Study Type
Observational
Participants
Expecting 100 study participants
Last Updated